Biotech Industry Examiner’s Post

CD-38 Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | Major Players – Ipsen, Janssen, Sanofi, Pfizer, GSK #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Hidradenitis Suppurativa Clinical Trials 2024: FDA Approvals, Pipeline, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight: Hidradenitis Suppurativa Clinical Trials Hidradenitis Suppurativa companies are Kymera Therapeutics, Novartis, Incyte Corporation, Pfizer, Lytix Biopharma, Aclaris Therapeutics, AbbVie, Azora Therapeutics, InflaRx, UCB, ChemoCentryx, Amgen, Eli Lilly, Janssen Biotech, Boehringer Ingelheim, CSL Behring, and others. (Albany, United States) As per … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

A quick pitch - Pfizer (NYSE:PFE) On the 30th of January, Pfizer will announce its Q4 2023 results after the company has lost more than $100bn of its market capitalization since January 2023(1), due to COVID-related inventory write-offs of $5.6bn in 2023(2) and growing investor concerns over revenue growth and margin sustainability as the company guides lower than expected(3), and finally, the development of its experimental obesity pill coming to a halt while its competitors - Ely Lilly and Novo Nordisk march forward with their own obesity drugs(4). Here is why I included Pfizer in my portfolio in January 2024: a. Defensive positioning paying high dividends at an attractive valuation - With a 3Y market beta below 0.5, a forward dividend yield of 5.9%, at 19x forward PE ratio including lower guidance, below its peers' average, a formidable balance sheet, and a historically consistent cash flows(5), Pfizer is well positioned to withstand a turbulent market and compensate its shareholders with an unbalanced risk/reward metric. b. Seagen's $43bn acquisition - The cancer therapeutics market size is expected to grow at a CAGR of +9% from 2023 to 2032(6), and Pfizer's recent acquisition of Seagen, completed in late 2023, sets it to grow in parallel, strengthening Pfizer's roughly 20% oncology treatments share of total revenue and its overall top-line growth in consequence. Seagen added 4 existing products to Pfizer's portfolio and doubled its oncology pipeline(7). c. Strong foundation, innovative pipeline, and excellent M&A - In addition to Pfizer's existing products that sustain a strong cash flow, the company has a pipeline of 83 projects, 23 of them in phase 3 already, focusing on oncology, vaccines, and blood diseases(7). Also, Pfizer is a serial buyer, where it historically has been able to create value through acquisitions, target major growth areas, and remain a leader in the pharmaceutical industry(8). Sources: (1) CapitalIQ as of 19.01.2024, (2) www.fiercepharma.com, (3) www.cnbc.com, (4) www.cnbc.com, (5) CapitalIQ as of 19.01.2024, (6) www.precedenceresearch.com, (7) www.pfizer.com, (8) www.investopedia.com #mergersandacquisitions #investing

📊 Top Pharmas by 2024 Pipeline Size 👇 🏆 Roche leads the ranking with 218 products in the R&D pipeline closely followed by Pfizer. 🔎 Among the top 15 companies based on products in the pipeline, 6 were from the United States. 📈 R&D trends include a resurgence in investment and pipeline activity with a focus on obesity drugs, radiopharmaceuticals, and targeted therapies in oncology. As I am seeing a lot of discussions around large pharma R&D productivity - let's also consider R&D investments per company 👇 Merck - $30.5 billion Roche- $15.56 billion Johnson & Johnson– $15.09 billion Novartis– $ 11.37 billion AstraZeneca– $10.94 billion Pfizer– $10.58 billion Eli Lilly and Company- $9.31 billion Bristol Myers Squibb– $9.21 billion AbbVie– $7.68 billion Sanofi– $7.18 billion Investments represented here are strategic acquisitions to expand a company’s prowess in a particular area - or investments for in-licensing drug candidates to beef up their pipelines. Data: As of January 2024 🙏 Sources: Citeline, Pharmaceutical Technology & Company Annual reports 👩⚕️ 💊 Have you joined the MSL and medical affairs linkedin community yet? Over 21.000 med. affairs professionals across the globe sharing jobs, tips and actively networking. 🛎 👉 This is the link: https://lnkd.in/eKQNrKM Nice post by Nicolas Schmitz

Eli Lilly ($LLY) to Buy Morphic Holding ($MORF) for $3.2 Billion Eli Lilly has agreed to acquire biopharmaceutical company Morphic Holding for $3.2 billion, enhancing its immunology pipeline per a press release from Lilly entitled:   “Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease.” In pre-market trading, shares of Morphic are +75%, trading at near the $56 level on heavy volume of 4 million shares. Morphic’s average daily trading volume is 512K shares.   Eli Lilly announced on Monday that it will pay $57 per share for Morphic, representing a 79% premium over Morphic's closing price of $31.84 on Friday. Morphic, based in Waltham, Massachusetts, is focused on developing therapies for serious chronic diseases, with its lead program targeting inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Late last year, Eli Lilly received U.S. Food and Drug Administration approval for its Omvoh treatment for moderately to severely active ulcerative colitis in adults. Indianapolis-based Eli Lilly anticipates completing the acquisition, which is not subject to any financing conditions, in the third quarter.

Don't miss the coverage in Philadelphia Business Journal where AscellaHealth CEO, Dea Belazi provides key insights on how our tailored specialty pharmaceutical solutions are optimizing patient outcomes and cost savings for clients. Read more: https://lnkd.in/eCeaNusd #lifesciences #pharmaceutical #FollowAscellaHealth #specialtypharmacy 

Interesting Article… "𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐏𝐚𝐫𝐞𝐧𝐭𝐞𝐫𝐚𝐥 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 & 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠" In a discussion hosted by DCAT Value Chain Insights, Claus Feussner (SVP of Development Service at Vetter Pharma) and John Cameron (Director of the Global Injectables Platform at Corden Pharma - A Full-Service CDMO) offered their perspectives on the key trends in parenteral drug development and manufacturing. 👉 Here are the key points: 𝐒𝐡𝐢𝐟𝐭 𝐓𝐨𝐰𝐚𝐫𝐝𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐱 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬: There's a notable move towards developing complex and large-molecule biologics, particularly for targeting specific cancer indications via immunotherapy. 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐨𝐧𝐯𝐞𝐧𝐢𝐞𝐧𝐜𝐞: There's an ongoing transition towards improving patient convenience through self-administration, leading to the development of patient-friendly delivery systems for at-home administration. 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧: Digitalisation, including artificial intelligence, machine learning, and robotics, is streamlining production processes, enhancing efficiency, and providing insights into unique development processes. 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 (𝐄𝐔 𝐆𝐌𝐏 𝐀𝐧𝐧𝐞𝐱 𝟏): The revised Annex 1 emphasises contamination-control strategy and compliance-management systems to enhance the overall quality and safety of sterile drug products. In summary, the parenteral drug development and manufacturing landscape is evolving rapidly, driven by scientific advancements, patient needs, and regulatory changes. These trends shape the future of healthcare delivery and therapeutic options for patients worldwide. 🔬🚀 #cdmo #pharma #biopharma #biotech

BREAKING PHARMA NEWS= Lykos Therapeutics Announces Leadership Transition Amid Regulatory Setback September 5, 2024 — In a significant leadership transition, Lykos Therapeutics has announced that Amy Emerson will step down from her longtime role as CEO. This change comes on the heels of the U.S. Food and Drug Administration's (FDA) decision to decline approval for the company's MDMA-based treatment for post-traumatic stress disorder (PTSD), citing the need for an additional late-stage trial. Michael Mullette, who has served as Lykos's Chief Operating Officer since early 2022, has been appointed as interim CEO. Mullette brings over 20 years of pharmaceutical industry experience, including notable tenures at Sanofi and Moderna, where he played a pivotal role in the commercialization of Moderna's COVID-19 vaccine. "Amy's contributions to Lykos, and to innovation in the field of mental healthcare more broadly, cannot be overstated" said Jeff George, Chairman of the Lykos Board of Directors. In addition to Mullette's appointment, Dr. David Hough will step in as Chief Medical Officer. With nearly two decades at Johnson & Johnson, Dr. Hough's expertise in central nervous system drug development is expected to strengthen Lykos's clinical pursuit of FDA approval for its flagship therapeutic offering, midomafetamine. Emerson will continue to support Lykos as a senior advisor and observer on the board through the end of the year. Lykos's transition follows the laying off of 75% of its workforce and the departure of founder Rick Doblin from the board—clear indicators of a strategic pivot as the company recalibrates its path forward. The road ahead may be challenging, but with seasoned leaders like Mullette and Hough at the helm, Lykos remains committed to its mission of groundbreaking advancements in mental healthcare. #pharma #biotech #breakingnews

📊 Top Pharmas by 2024 Pipeline Size 👇 🏆 Roche leads the ranking with 218 products in the R&D pipeline closely followed by Pfizer. 🔎 Among the top 15 companies based on products in the pipeline, 6 were from the United States. 📈 R&D trends include a resurgence in investment and pipeline activity with a focus on obesity drugs, radiopharmaceuticals, and targeted therapies in oncology. As I am seeing a lot of discussions around large pharma R&D productivity - let's also consider R&D investments per company 👇 Merck - $30.5 billion Roche- $15.56 billion Johnson & Johnson– $15.09 billion Novartis– $ 11.37 billion AstraZeneca– $10.94 billion Pfizer– $10.58 billion Eli Lilly and Company- $9.31 billion Bristol Myers Squibb– $9.21 billion AbbVie– $7.68 billion Sanofi– $7.18 billion Investments represented here are strategic acquisitions to expand a company’s prowess in a particular area - or investments for in-licensing drug candidates to beef up their pipelines. Data: As of January 2024 🙏 Sources: Citeline, Pharmaceutical Technology & Company Annual reports 👩⚕️ 💊 Have you joined the MSL and medical affairs linkedin community yet? Over 21.000 med. affairs professionals across the globe sharing jobs, tips and actively networking. 🛎 👉 This is the link: https://lnkd.in/gZ_mBprH Nice post by Nicolas Schmitz

🧬 The BioTech $100-billion Club 🧬 While the biotech industry has been faced difficultly in recent times, upward trajectory is back on the horizon. Numerous big biotech names have been able to capitalise on their landmark products to launch new innovative projects. Faced with financial challenges, the leaders of the industry have been able to adapt to the changing dynamics of the market. At a time when the industry is set to recover, the companies in this list will play an important role in the developments of this year and beyond. Heres an quick overview of some top BioTech companies leading the way with over 100 billion market cap behind them 👉 1 - Eli Lilly and Company – $717 billion 2 - Novo Nordisk – $561 billion 3 - Johnson & Johnson – $389 billion 4 - Merck Group – $322 billion 5 - AbbVie – $314 billion 6 - Novartis – $205 billion 7 - AstraZeneca – $196 billion 8 - Roche – $190 billion 9 - Pfizer – $150 billion 10 - Amgen – $148 billion 11 - Vertex Pharmaceuticals – $112 billion 12 - Sanofi – $110 billion 13 - Regeneron – $108 billion 14 - Bristol Myers Squibb – $102 billion #BioTech #biotechnology #marketcapitalization #pharma https://lnkd.in/ekPGyC2u